 | • レポートコード：MRC2312MG15402 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のターゲット腫瘍薬市場規模と予測を収録しています。・世界のターゲット腫瘍薬市場：売上、2018年-2023年、2024年-2029年 ・世界のターゲット腫瘍薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のターゲット腫瘍薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「キナーゼ阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 ターゲット腫瘍薬のグローバル主要企業は、AbbVie、 Johnson & Johnson、 Novartis、 Gilead Sciences、 Roche、 Bristol-Myers Squibb、 Amgen、 AstraZeneca、 Merck & Co、 Takeda、 Merck KGaA、 Seagen、 Eli Lilly、 Ono Pharmaceutical、 Pfizer、 GSK、 Exelixis、 Regeneron、 Innovent、 Hengrui Medicineなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、ターゲット腫瘍薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のターゲット腫瘍薬市場：タイプ別、2018年-2023年、2024年-2029年 世界のターゲット腫瘍薬市場：タイプ別市場シェア、2022年 ・キナーゼ阻害剤、モノクローナル抗体、PARP阻害剤、その他 世界のターゲット腫瘍薬市場：用途別、2018年-2023年、2024年-2029年 世界のターゲット腫瘍薬市場：用途別市場シェア、2022年 ・肺がん、乳がん、前立腺がん、血液がん、その他 世界のターゲット腫瘍薬市場：地域・国別、2018年-2023年、2024年-2029年 世界のターゲット腫瘍薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるターゲット腫瘍薬のグローバル売上、2018年-2023年 ・主要企業におけるターゲット腫瘍薬のグローバル売上シェア、2022年 ・主要企業におけるターゲット腫瘍薬のグローバル販売量、2018年-2023年 ・主要企業におけるターゲット腫瘍薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 AbbVie、 Johnson & Johnson、 Novartis、 Gilead Sciences、 Roche、 Bristol-Myers Squibb、 Amgen、 AstraZeneca、 Merck & Co、 Takeda、 Merck KGaA、 Seagen、 Eli Lilly、 Ono Pharmaceutical、 Pfizer、 GSK、 Exelixis、 Regeneron、 Innovent、 Hengrui Medicine ************************************************************* ・調査・分析レポートの概要 ターゲット腫瘍薬市場の定義 市場セグメント 世界のターゲット腫瘍薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のターゲット腫瘍薬市場規模 世界のターゲット腫瘍薬市場規模：2022年 VS 2029年 世界のターゲット腫瘍薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのターゲット腫瘍薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のターゲット腫瘍薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：キナーゼ阻害剤、モノクローナル抗体、PARP阻害剤、その他 ターゲット腫瘍薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：肺がん、乳がん、前立腺がん、血液がん、その他 ターゲット腫瘍薬の用途別グローバル売上・予測 ・地域別市場分析 地域別ターゲット腫瘍薬市場規模 2022年と2029年 地域別ターゲット腫瘍薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） AbbVie、 Johnson & Johnson、 Novartis、 Gilead Sciences、 Roche、 Bristol-Myers Squibb、 Amgen、 AstraZeneca、 Merck & Co、 Takeda、 Merck KGaA、 Seagen、 Eli Lilly、 Ono Pharmaceutical、 Pfizer、 GSK、 Exelixis、 Regeneron、 Innovent、 Hengrui Medicine ... |
This research report provides a comprehensive analysis of the Targeted Oncology Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Targeted Oncology Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Targeted Oncology Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Targeted Oncology Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Targeted Oncology Drugs market presents opportunities for various stakeholders, including Lung Cancer, Breast Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Targeted Oncology Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Targeted Oncology Drugs market was valued at US$ 105830 million in 2022 and is projected to reach US$ 171400 million by 2029, at a CAGR of 7.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Precision cancer medicine, also known as personalized or targeted cancer therapy, is driven by the growing understanding of cancer’s molecular and genetic complexity. Advances in genomics and biomarker identification have enabled the development of therapies tailored to an individual’s specific cancer characteristics. This approach offers the potential for more effective treatments with fewer side effects compared to traditional chemotherapy. The market benefits from increasing research in oncology, the rise of precision diagnostics, and the growing availability of targeted therapies. However, challenges include the high cost of genetic testing and targeted treatments, as well as the need for comprehensive molecular profiling. Additionally, regulatory approvals and insurance coverage for these therapies can be complex. To maximize the potential of precision cancer medicine, stakeholders must address these challenges, improve accessibility, and continue research into novel biomarkers and therapies to provide tailored cancer care for patients.
Key Features:
The research report on the Targeted Oncology Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Targeted Oncology Drugs market.
Market Overview: The report provides a comprehensive overview of the Targeted Oncology Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Kinase Inhibitors, Monoclonal Antibodies), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Targeted Oncology Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Targeted Oncology Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Targeted Oncology Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Targeted Oncology Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Targeted Oncology Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Targeted Oncology Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Targeted Oncology Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Targeted Oncology Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Targeted Oncology Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Kinase Inhibitors
Monoclonal Antibodies
PARP Inhibitors
Other
Market segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
Global Targeted Oncology Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Outline of Major Chapters:
Chapter 1: Introduces the definition of Targeted Oncology Drugs, market overview.
Chapter 2: Global Targeted Oncology Drugs market size in revenue.
Chapter 3: Detailed analysis of Targeted Oncology Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Targeted Oncology Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Targeted Oncology Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Oncology Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Oncology Drugs Overall Market Size
2.1 Global Targeted Oncology Drugs Market Size: 2022 VS 2029
2.2 Global Targeted Oncology Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Oncology Drugs Players in Global Market
3.2 Top Global Targeted Oncology Drugs Companies Ranked by Revenue
3.3 Global Targeted Oncology Drugs Revenue by Companies
3.4 Top 3 and Top 5 Targeted Oncology Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Targeted Oncology Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Oncology Drugs Players in Global Market
3.6.1 List of Global Tier 1 Targeted Oncology Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Oncology Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Targeted Oncology Drugs Market Size Markets, 2022 & 2029
4.1.2 Kinase Inhibitors
4.1.3 Monoclonal Antibodies
4.1.4 PARP Inhibitors
4.1.5 Other
4.2 By Type – Global Targeted Oncology Drugs Revenue & Forecasts
4.2.1 By Type – Global Targeted Oncology Drugs Revenue, 2018-2023
4.2.2 By Type – Global Targeted Oncology Drugs Revenue, 2024-2029
4.2.3 By Type – Global Targeted Oncology Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Targeted Oncology Drugs Market Size, 2022 & 2029
5.1.2 Lung Cancer
5.1.3 Breast Cancer
5.1.4 Prostate Cancer
5.1.5 Blood-related Cancer
5.1.6 Other
5.2 By Application – Global Targeted Oncology Drugs Revenue & Forecasts
5.2.1 By Application – Global Targeted Oncology Drugs Revenue, 2018-2023
5.2.2 By Application – Global Targeted Oncology Drugs Revenue, 2024-2029
5.2.3 By Application – Global Targeted Oncology Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Targeted Oncology Drugs Market Size, 2022 & 2029
6.2 By Region – Global Targeted Oncology Drugs Revenue & Forecasts
6.2.1 By Region – Global Targeted Oncology Drugs Revenue, 2018-2023
6.2.2 By Region – Global Targeted Oncology Drugs Revenue, 2024-2029
6.2.3 By Region – Global Targeted Oncology Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Targeted Oncology Drugs Revenue, 2018-2029
6.3.2 US Targeted Oncology Drugs Market Size, 2018-2029
6.3.3 Canada Targeted Oncology Drugs Market Size, 2018-2029
6.3.4 Mexico Targeted Oncology Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Targeted Oncology Drugs Revenue, 2018-2029
6.4.2 Germany Targeted Oncology Drugs Market Size, 2018-2029
6.4.3 France Targeted Oncology Drugs Market Size, 2018-2029
6.4.4 U.K. Targeted Oncology Drugs Market Size, 2018-2029
6.4.5 Italy Targeted Oncology Drugs Market Size, 2018-2029
6.4.6 Russia Targeted Oncology Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Targeted Oncology Drugs Market Size, 2018-2029
6.4.8 Benelux Targeted Oncology Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Targeted Oncology Drugs Revenue, 2018-2029
6.5.2 China Targeted Oncology Drugs Market Size, 2018-2029
6.5.3 Japan Targeted Oncology Drugs Market Size, 2018-2029
6.5.4 South Korea Targeted Oncology Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Targeted Oncology Drugs Market Size, 2018-2029
6.5.6 India Targeted Oncology Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Targeted Oncology Drugs Revenue, 2018-2029
6.6.2 Brazil Targeted Oncology Drugs Market Size, 2018-2029
6.6.3 Argentina Targeted Oncology Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Targeted Oncology Drugs Revenue, 2018-2029
6.7.2 Turkey Targeted Oncology Drugs Market Size, 2018-2029
6.7.3 Israel Targeted Oncology Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Targeted Oncology Drugs Market Size, 2018-2029
6.7.5 UAE Targeted Oncology Drugs Market Size, 2018-2029
7 Targeted Oncology Drugs Companies Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Targeted Oncology Drugs Major Product Offerings
7.1.4 AbbVie Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.1.5 AbbVie Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Targeted Oncology Drugs Major Product Offerings
7.2.4 Johnson & Johnson Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Targeted Oncology Drugs Major Product Offerings
7.3.4 Novartis Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Gilead Sciences
7.4.1 Gilead Sciences Company Summary
7.4.2 Gilead Sciences Business Overview
7.4.3 Gilead Sciences Targeted Oncology Drugs Major Product Offerings
7.4.4 Gilead Sciences Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.4.5 Gilead Sciences Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Targeted Oncology Drugs Major Product Offerings
7.5.4 Roche Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.5.5 Roche Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Targeted Oncology Drugs Major Product Offerings
7.6.4 Bristol-Myers Squibb Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Amgen
7.7.1 Amgen Company Summary
7.7.2 Amgen Business Overview
7.7.3 Amgen Targeted Oncology Drugs Major Product Offerings
7.7.4 Amgen Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.7.5 Amgen Key News & Latest Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Company Summary
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Targeted Oncology Drugs Major Product Offerings
7.8.4 AstraZeneca Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.8.5 AstraZeneca Key News & Latest Developments
7.9 Merck & Co
7.9.1 Merck & Co Company Summary
7.9.2 Merck & Co Business Overview
7.9.3 Merck & Co Targeted Oncology Drugs Major Product Offerings
7.9.4 Merck & Co Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.9.5 Merck & Co Key News & Latest Developments
7.10 Takeda
7.10.1 Takeda Company Summary
7.10.2 Takeda Business Overview
7.10.3 Takeda Targeted Oncology Drugs Major Product Offerings
7.10.4 Takeda Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.10.5 Takeda Key News & Latest Developments
7.11 Merck KGaA
7.11.1 Merck KGaA Company Summary
7.11.2 Merck KGaA Business Overview
7.11.3 Merck KGaA Targeted Oncology Drugs Major Product Offerings
7.11.4 Merck KGaA Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.11.5 Merck KGaA Key News & Latest Developments
7.12 Seagen
7.12.1 Seagen Company Summary
7.12.2 Seagen Business Overview
7.12.3 Seagen Targeted Oncology Drugs Major Product Offerings
7.12.4 Seagen Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.12.5 Seagen Key News & Latest Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Company Summary
7.13.2 Eli Lilly Business Overview
7.13.3 Eli Lilly Targeted Oncology Drugs Major Product Offerings
7.13.4 Eli Lilly Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.13.5 Eli Lilly Key News & Latest Developments
7.14 Ono Pharmaceutical
7.14.1 Ono Pharmaceutical Company Summary
7.14.2 Ono Pharmaceutical Business Overview
7.14.3 Ono Pharmaceutical Targeted Oncology Drugs Major Product Offerings
7.14.4 Ono Pharmaceutical Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.14.5 Ono Pharmaceutical Key News & Latest Developments
7.15 Pfizer
7.15.1 Pfizer Company Summary
7.15.2 Pfizer Business Overview
7.15.3 Pfizer Targeted Oncology Drugs Major Product Offerings
7.15.4 Pfizer Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.15.5 Pfizer Key News & Latest Developments
7.16 GSK
7.16.1 GSK Company Summary
7.16.2 GSK Business Overview
7.16.3 GSK Targeted Oncology Drugs Major Product Offerings
7.16.4 GSK Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.16.5 GSK Key News & Latest Developments
7.17 Exelixis
7.17.1 Exelixis Company Summary
7.17.2 Exelixis Business Overview
7.17.3 Exelixis Targeted Oncology Drugs Major Product Offerings
7.17.4 Exelixis Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.17.5 Exelixis Key News & Latest Developments
7.18 Regeneron
7.18.1 Regeneron Company Summary
7.18.2 Regeneron Business Overview
7.18.3 Regeneron Targeted Oncology Drugs Major Product Offerings
7.18.4 Regeneron Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.18.5 Regeneron Key News & Latest Developments
7.19 Innovent
7.19.1 Innovent Company Summary
7.19.2 Innovent Business Overview
7.19.3 Innovent Targeted Oncology Drugs Major Product Offerings
7.19.4 Innovent Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.19.5 Innovent Key News & Latest Developments
7.20 Hengrui Medicine
7.20.1 Hengrui Medicine Company Summary
7.20.2 Hengrui Medicine Business Overview
7.20.3 Hengrui Medicine Targeted Oncology Drugs Major Product Offerings
7.20.4 Hengrui Medicine Targeted Oncology Drugs Revenue in Global Market (2018-2023)
7.20.5 Hengrui Medicine Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer